The 36-month beta value for IONS is at 0.24. Analysts have varying views on the stock, with 13 analysts rating it as a “buy,” 4 rating it as “overweight,” 7 as “hold,” and 0 as “sell.”
The public float for IONS is 154.59M, and currently, shorts hold a 8.31% of that float. The average trading volume for IONS on March 21, 2025 was 1.64M shares.
IONS) stock’s latest price update
The stock of Ionis Pharmaceuticals Inc (NASDAQ: IONS) has decreased by -1.83 when compared to last closing price of 33.34. Despite this, the company has experienced a -0.52% fall in its stock price over the last five trading sessions. businesswire.com reported 2025-03-11 that OSAKA, Japan–(BUSINESS WIRE)–Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “ONO”) announced that it has entered into a license agreement with Ionis Pharmaceuticals, Inc. (Carlsbad, CA,U.S.; CEO, Brett P. Monia, Ph.D.; “Ionis”) for sapablursen, an investigational RNA-targeted medicine for the treatment of polycythemia vera (PV). Sapablursen is currently being evaluated in adult patients with PV in the fully enrolled Phase 2 IMPRSSION study. Sapablu.
IONS’s Market Performance
IONS’s stock has fallen by -0.52% in the past week, with a monthly rise of 2.89% and a quarterly drop of -14.09%. The volatility ratio for the week is 3.66% while the volatility levels for the last 30 days are 4.33% for Ionis Pharmaceuticals Inc The simple moving average for the last 20 days is -0.47% for IONS stock, with a simple moving average of -17.25% for the last 200 days.
Analysts’ Opinion of IONS
Many brokerage firms have already submitted their reports for IONS stocks, with BMO Capital Markets repeating the rating for IONS by listing it as a “Market Perform.” The predicted price for IONS in the upcoming period, according to BMO Capital Markets is $60 based on the research report published on August 02, 2024 of the previous year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see IONS reach a price target of $62, previously predicting the price at $53. The rating they have provided for IONS stocks is “Outperform” according to the report published on July 24th, 2024.
Jefferies gave a rating of “Buy” to IONS, setting the target price at $75 in the report published on July 16th of the previous year.
IONS Trading at -0.10% from the 50-Day Moving Average
After a stumble in the market that brought IONS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.47% of loss for the given period.
Volatility was left at 4.33%, however, over the last 30 days, the volatility rate increased by 3.66%, as shares surge +0.12% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.02% lower at present.
During the last 5 trading sessions, IONS fell by -0.52%, which changed the moving average for the period of 200-days by -12.88% in comparison to the 20-day moving average, which settled at $32.88. In addition, Ionis Pharmaceuticals Inc saw -6.38% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IONS starting from Monia Brett P, who sale 140 shares at the price of $32.32 back on Mar 11 ’25. After this action, Monia Brett P now owns 180,980 shares of Ionis Pharmaceuticals Inc, valued at $4,525 using the latest closing price.
Monia Brett P, the Officer of Ionis Pharmaceuticals Inc, proposed sale 140 shares at $32.32 during a trade that took place back on Mar 11 ’25, which means that Monia Brett P is holding shares at $4,525 based on the most recent closing price.
Stock Fundamentals for IONS
Current profitability levels for the company are sitting at:
- -0.67 for the present operating margin
- 0.97 for the gross margin
The net margin for Ionis Pharmaceuticals Inc stands at -0.64. The total capital return value is set at -0.18. Equity return is now at value -93.03, with -15.13 for asset returns.
Based on Ionis Pharmaceuticals Inc (IONS), the company’s capital structure generated 0.71 points at debt to capital in total, while cash flow to debt ratio is standing at -0.35. The debt to equity ratio resting at 2.41. The interest coverage ratio of the stock is -5.53.
Currently, EBITDA for the company is -475.08 million with net debt to EBITDA at -3.28. When we switch over and look at the enterprise to sales, we see a ratio of 9.04. The receivables turnover for the company is 7.65for trailing twelve months and the total asset turnover is 0.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.47.
Conclusion
In conclusion, Ionis Pharmaceuticals Inc (IONS) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
